Human Reproductive Technologies Market Expected to Reach USD 27.1 Billion Globally in 2019: Transparency Market Research

Description

Human Reproductive TechnologiesHuman Reproductive Technologies Market Expected to Reach USD 27.1 Billion Globally in 2019: Transparency Market Research PR Newswire ALBANY, New York, April 14, 2014 According to a new market report published by Transparency Market Research "Human Reproductive Technologies Market (Infertility: Drugs and Procedures & Contraceptives: Drugs and Devices) - Global Industry Analysis, Size, Procedures, Share, Growth, Trends and Forecast, 2013 - 2019," the global market for human reproductive technologies was valued at USD 23.0 billion in 2012 and is expected to reach USD 27.1 billion in 2019, growing at a CAGR of 2.2% from 2013 to 2019. Human reproductive technologies include procedures and therapies for conceiving or controlling pregnancy by means of artificial and/or semi artificial medical solutions. Lack of awareness about the reproductive deficiencies and their treatment necessity and availability has been limiting the market to explore its potential value. Therefore, awareness strategies adopted by market players with proper guidance for patients will fuel the emerging human reproductive technologies market especially the infertility treatment market. Developing regions such as the Asia-Pacific, Latin America, Africa and Middle-East hold the maximum growth potential in the human reproductive technologies market.

Informations

• Publié par: transparency-market-research
• Publié le: 14 avril 2014
• Nombre de lectures: 4
• Langue: English

Extrait

Human Reproductive Technologies Market Expected to Reach USD 27.1 Billion Globally in 2019: Transparency Market Research

PR Newswire

ALBANY, New York, April 14, 2014



According to a new market report published by Transparency Market Research "Human Reproductive Technologies Market (Infertility: Drugs and Procedures & Contraceptives: Drugs and Devices) - Global Industry Analysis, Size, Procedures, Share, Growth, Trends and Forecast, 2013 - 2019," the global market for human reproductive technologies was valued at USD 23.0 billion in 2012 and is expected to reach USD 27.1 billion in 2019, growing at a CAGR of 2.2% from 2013 to 2019.

Human reproductive technologies include procedures and therapies for conceiving or controlling pregnancy by means of artificial and/or semi artificial medical solutions. Lack of awareness about the reproductive deficiencies and their treatment necessity and availability has been limiting the market to explore its potential value. Therefore, awareness strategies adopted by market players with proper guidance for patients will fuel the emerging human reproductive technologies market especially the infertility treatment market. Developing regions such as the Asia-Pacific, Latin America, Africa and Middle-East hold the maximum growth potential in the human reproductive technologies market. Some of the other factors contributing to the growth of human reproductive technologies market include delay in conceiving, lifestyle habits such as smoking, excessive alcohol consumption, increasing use of contraceptive pills and devices, and rising incidences of infertility.

Browse Global Human Reproductive Technologies Market Report with Full TOC at http://www.transparencymarketresearch.com/human-reproductive-technologies-market.html

The infertility treatment market is characterized by the presence of many leading patented drug brands which are restraining the entry of generics and hence, creating a monopolistic situation. In addition, due to patient sentiments attached to infertility treatment procedures, risk ofno conception due to a low-quality generic drugis usually avoided. This report includes market analysis for seven major (by sales) branded formulations of infertility drugs, namely, Gonal-f, Follistim AQ, AndroGel, Testim, Viagra, Cialis and Levitra/Staxyn. Similarly, the contraceptive drugs and devices market has many drugs in the research pipeline awaiting commercialization to grab a share of this potential market. Large and well established pharmaceutical players such as Merck Serono, Merck & Co., Inc., Bayer AG, Pfizer, Inc., Actavis plc, Ferring International Center S.A. and Teva Pharmaceutical Industries Ltd. dominate the human reproductive technologies market.

The global contraceptives market was valued at USD 16.0billion in 2012 and is expected to grow at a CAGR of 5.5% from 2013 to 2019. The oral contraceptive pills market lead the overall contraceptives market in 2012 in terms of revenue, mainly due to increasing population awareness through advertisements enabling patients to buy them over-the-counter. In the contraceptive devices market, male condoms formed the largest market segment owing to the increased accessibility and awareness along with their ease of use.

The infertility drugs market studied in this report include leading brands from three drug classes, namely, gonadotropins, androgens and erectile dysfunction drugs. Among these, Viagra was the largest brand by revenue in 2012 among others considered in the study due to increasing cases of erectile dysfunction in male infertility. Moreover, it has been a well-established and popular brand since its approval in 1998 by the U.S. FDA. Gonal-f in the gonadotropin class is the leading brand prescribed by majority of the infertility specialist due to better results achieved using it. For testosterone deficiency which is one of the major infertility causes in male patients, AndroGel is the blockbuster drug being preferred for the treatment. Generic manufacturers such as Watson Pharmaceuticals and Par Pharmaceuticals are expected to enter the market with their generic versions by 2015.

Among the infertility procedures, intrauterine insemination (IUI) is the most preferred treatment procedure due to its low operational cost and equal success rate compared to intracytoplasmic sperm injection (ICSI) and in vitro fertilization (IVF), which follow IUI in terms of preference. The simplicity of performing IUI is what attracts the healthcare professionals to prefer this procedure over others. Zygote intrafallopian transfer (ZIFT) and gamete intrafallopian transfer (GIFT) are the least popular procedures performed worldwide, accounting for about 0.1% of the total ART treatments. This is due to the higher procedural costs and complexity in performing these procedures.

Related & Recently Published Reports by Transparency Market Research 

• Microserver Market: http://www.transparencymarketresearch.com/microserver-market.html
• Infusion Pumps Market: http://www.transparencymarketresearch.com/infusion-systems-market.html
• UHT Milk Market: http://www.transparencymarketresearch.com/uht-milk-market.html
• Nanocoatings Market: http://www.transparencymarketresearch.com/nanocoatings-market.html
• Calcium Carbonate Market: http://www.transparencymarketresearch.com/calcium-carbonate-market.html
• Naphtha Market: http://www.transparencymarketresearch.com/naphtha-market.html
• Web Content Filtering Market: http://www.transparencymarketresearch.com/web-content-filtering-market.html

North America dominated the global human reproductive technologies market in 2012 and is expected to maintain its leading market position till 2019. However, the Asia-Pacific contraceptive technologies market is estimated to grow at a faster pace (CAGR of 6.9% from 2013 to 2019) mainly to the rising awareness and acceptance of reproductive technologies in this region. Entry of large market players such as Merck Serono, Ferring International Center S.A. and Merck & Co., Inc.will also drive the market in the Asia-Pacific region.

Some of the key players in the global human reproductive technologies market include Abbott Laboratories, Bayer AG, Merck & Co., Inc., Merck Serono, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Watson Pharmaceuticals and Reckitt Benckiser.

The global human reproductive technologies market is categorized into the following segments:

Human Reproductive Technologies Market, by Infertility Drugs 

Gonal-f (recombinant follitropin alfa)

Follistim AQ (follitropin beta)

AndroGel (testosterone)

Testim (testosterone)

Viagra (sildenafil citrate)

Cialis (tadalafil)

Levitra/Staxyn (vardenafil)

Browse Global Human Reproductive Technologies Market Report with Full TOC at http://www.transparencymarketresearch.com/human-reproductive-technologies-market.html

Human Reproductive Technologies Market, by Infertility Procedures 

In Vitro Fertilization (IVF)

Intracytoplasmic Sperm Injection (ICSI)

Zygote Intrafallopian Transfer (ZIFT)

Gamete Intrafallopian Transfer (GIFT)

Intrauterine Insemination (IUI)

Human Reproductive Technologies Market, by Contraceptive Technologies 

Drugs

• Oral Contraceptive Pills
• Contraceptive Injectables
• Topical Contraceptives

Devices

• Male Contraceptive Devices (Male Condoms)
• Female Contraceptive Devices
  • Female Condoms
  • Diaphragms
  • Sponges
  • IUDs
    • Hormonal IUDs
    • Copper IUDs
  • Subdermal Contraceptive Implants
  • Vaginal Rings

Human Reproductive Technologies Market,by Geography 

North America

Europe

Asia-Pacific

Rest of the World (RoW)

Browse Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us 

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.